Tagged with Moderna

LatAm The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s vaccine and approval of three new cannabis-based products.   Moderna partners with Latin American Pharma https://endpts.com/covid-19-roundup-scottish-government-invests-27m-in-valnevas-covid-19-manufacturing-moderna-partners-with-latin-american-pharma/ In a move to…

Global Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time in high-income countries, the developing world risks falling behind. Less than ten percent of the African continent has been vaccinated,…

Spain The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and the health technology sector’s request to the administration.   Grifols will use funds from GIC to reduce its debt (The…

USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Asia-Pacific The latest pharma news from the Asia-Pacific region, including upcoming IPOs for Prestige Biopharma and HH&L Acquisition; logistics challenges for COVID-19 vaccine distributors; and Moderna’s CMO-based vaccine manufacturing strategy in Asia.   Singapore-based Prestige Biopharma prepares for IPO on the Korea Exchange https://www.businesstimes.com.sg/garage/prestige-biopharma-eyes-at-least-18t-won-valuation-in-korean-ipo SINGAPORE-BASED Prestige Biopharma expects an implied market…

Rankings Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living cells that selectively “turns off” specific gene’s expressions, thereby affecting the production of a specific protein that contributes to disease.…